Clinical experience with open-label topiramate use in infants younger than 2 years of age. (Q35132987)

6 August 2017

title

Clinical experience with open-label topiramate use in infants younger than 2 years of age. (English)

1 reference

6 August 2017

9

Tally Lerman-Sagie

1 reference

6 August 2017

1

Nathan Watemberg

1 reference

6 August 2017

author name string

Hadassah Goldberg-Stern

2

1 reference

6 August 2017

Bruria Ben-Zeev

3

1 reference

6 August 2017

Itai Berger

4

1 reference

6 August 2017

Rachel Straussberg

5

1 reference

6 August 2017

Sara Kivity

6

1 reference

6 August 2017

Uri Kramer

7

1 reference

6 August 2017

Nathan Brand

8

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Journal of Child Neurology

6 August 2017

published in

1 reference

6 August 2017

volume

18

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

258-262

1 reference

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

A pilot study of topiramate in the treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Benign idiopathic partial epilepsies in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Effects of topiramate on cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Postmarketing experience with topiramate and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Factors associated with behavioral and cognitive abnormalities in children receiving topiramate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Topiramate YTC/YTCE Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

When antiepileptic drugs aggravate epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

Antiepileptic drugs as a cause of worsening seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738030180040901

10.1177/08830738030180040901

21 January 2018

Identifiers

DOI

0 references

1 reference